- Assessment of Cardiovascular Risk in HIV Patients
Past research has shown that individuals with HIV may be at greater risk for heart disease than the general population. In this study we will follow HIV-infected men and women and HIV-negative men and women every 6 months over a 2 year period.
The potential benefits from this study include evaluation of overall body composition, cardiovascular health, glucose tolerance, and insulin metabolism. Subjects will be compensated up to $300.
Eligibility criteria include: HIV positive and negative males and females, ages 18-65. Subjects who are HIV positive need to be on a stable treatment regimen for more than 6 months and need to have a CD4 count greater than 350 cells/mm3.
The potential benefits from this study include evaluation of overall body composition, cardiovascular health, glucose tolerance, and insulin metabolism. Subjects will be compensated up to $300.
Eligibility criteria include: HIV positive and negative males and females, ages 18-65. Subjects who are HIV positive need to be on a stable treatment regimen for more than 6 months and need to have a CD4 count greater than 350 cells/mm3.
Institution – MGH - Massachusetts General Hospital, Boston, MA
Principal Investigator – Steven K Grinspoon, MD
Enrollment Information
For further information about enrolling a patient in this trial, contact the person below.
Name – Kathleen V Ftch, NP
Email – kfitch@partners.org
Phone – 617-724-8015
